Patents by Inventor Jean-Christophe Audonnet
Jean-Christophe Audonnet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10801039Abstract: The present invention encompasses BTV and ASHV vaccines or compositions and methods of producing recombinant reassortant BTV and ASHV vectors and methods of vaccination against BTV and ASHV.Type: GrantFiled: June 13, 2013Date of Patent: October 13, 2020Assignees: THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW, Boehringer Ingelheim Animal Health USA Inc.Inventors: Massimo Palmarini, Sandro Filipe Nunes, Pascal Hudelet, Jean Christophe Audonnet
-
Patent number: 10632182Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for freeze-drying biological preparations, including peptides, antigens, antibodies, and especially, cells. Importantly, the disclosed methods preserve the viability, infectivity and immunogenicity of cells from the Apicomplexa phylum, the Sarcocystidae family, and in particular, cells from the Toxoplasma genus.Type: GrantFiled: May 13, 2015Date of Patent: April 28, 2020Inventors: Noel Yves Henri Jean Genin, Jean-Christophe Audonnet, Didier Roy, Edouard Seche, Patrick Gervais, Samira Khaldi-Plassart, Romain Useo, Joelle DeConinck
-
Patent number: 10363300Abstract: The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV. The invention further encompasses methods of making or producing antigenic polypeptides or antigens.Type: GrantFiled: February 5, 2018Date of Patent: July 30, 2019Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.Inventors: Jean-Christophe Audonnet, Frédéric Reynard, Natalia Bomchil, Cécile Sigoillot-Claude
-
Patent number: 10350287Abstract: The present invention provides vectors that contain and express in vivo or in vitro one or more Hendra virus polypeptides or antigens that elicit an immune response in animal or human against Hendra virus and Nipah virus, compositions comprising said vectors and/or Hendra virus polypeptides, methods of vaccination against Hendra virus and Nipah virus, and kits for use with such methods and compositions.Type: GrantFiled: August 10, 2016Date of Patent: July 16, 2019Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.Inventors: Jean-Christophe Audonnet, Jules Maarten Minke, Teshome Mebatsion, Catherine Charreyre
-
Patent number: 10125401Abstract: The present invention relates to methods of differentiating and characterizing IBV, CSFV and NDV strains, and identifying new strains using high resolution melt technology. The present invention also provides primers and kits for use with such methods.Type: GrantFiled: December 17, 2013Date of Patent: November 13, 2018Assignee: ASIA-PACIFIC SPECIAL NUTRIENTS SDN. BHD.Inventors: Jean-Christophe Audonnet, Seetha Jaganathan
-
Patent number: 10076566Abstract: The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus.Type: GrantFiled: March 29, 2016Date of Patent: September 18, 2018Assignee: Merial Inc.Inventors: Jean-Christophe Audonnet, Jules Minke
-
Publication number: 20180236056Abstract: The invention provides novel methods and compositions for the vaccination of porcine animals against porcine reproductive and respiratory syndrome virus (PRRSV). Described herein are immunological and/or vaccine compositions comprising a DNA vector encoding a PRRSV protein, particularly a truncated ORF7 protein, which are administered to porcines using needle-free delivery. The plasmid can include more than one nucleic acid molecule such that the plasmid can express more than one antigen. Also disclosed are methods for using and kits employing such compositions.Type: ApplicationFiled: April 27, 2017Publication date: August 23, 2018Applicants: MERIAL INC., CHULALONGKORN UNIVERSITYInventors: Sanipa Suradhat, Jean-Christophe Audonnet, Catherine Charreyre
-
Patent number: 10010605Abstract: The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.Type: GrantFiled: September 23, 2015Date of Patent: July 3, 2018Assignee: Merial, Inc.Inventors: Jean-Christophe Audonnet, Zahia Hannas-Djebbara, Teshome Mebatsion, Yu-Wei Chiang, Justin Widener, Frédéric Reynard
-
Publication number: 20180169216Abstract: The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV. The invention further encompasses methods of making or producing antigenic polypeptides or antigens.Type: ApplicationFiled: February 5, 2018Publication date: June 21, 2018Applicant: MERIAL INC.Inventors: Jean-Christophe Audonnet, Frédéric Reynard, Natalia Bomchil, Cécile Sigoillot-Claude
-
Patent number: 9913891Abstract: The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV. The invention further encompasses methods of making or producing antigenic polypeptides or antigens.Type: GrantFiled: November 16, 2016Date of Patent: March 13, 2018Assignee: MERIAL INC.Inventors: Jean-Christophe Audonnet, Frédéric Reynard, Natalia Bomchil, Cécile Sigoillot-Claude
-
Patent number: 9669085Abstract: The invention provides novel methods and compositions for the vaccination of porcine animals against porcine reproductive and respiratory syndrome virus (PRRSV). Described herein are immunological and/or vaccine compositions comprising a DNA vector encoding a PRRSV protein, particularly a truncated ORF7 protein, which are administered to porcines using needle-free delivery. The plasmid can include more than one nucleic acid molecule such that the plasmid can express more than one antigen. Also disclosed are methods for using and kits employing such compositions.Type: GrantFiled: May 24, 2012Date of Patent: June 6, 2017Assignees: MERIAL INC., Chulalongkorn UniversityInventors: Sanipa Suradhat, Jean-Christophe Audonnet, Catherine Charreyre
-
Publication number: 20170143819Abstract: The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV. The invention further encompasses methods of making or producing antigenic polypeptides or antigens.Type: ApplicationFiled: November 16, 2016Publication date: May 25, 2017Applicant: MERIAL INC.Inventors: Jean-Christophe Audonnet, Frédéric Reynard, Natalia Bomchil, Cécile Sigoillot-Claude
-
Publication number: 20170087230Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for freeze-drying biological preparations, including peptides, antigens, antibodies, and especially, cells. Importantly, the disclosed methods preserve the viability, infectivity and immunogenicity of cells from the Apicomplexa phylum, the Sarcocystidae family, and in particular, cells from the Toxoplasma genus.Type: ApplicationFiled: May 13, 2015Publication date: March 30, 2017Applicants: MERIAL INC., VITAMFERO S.A, L'Universite De Bourgogne, L'Institut National Superieur des Sciences Agronom iques de L'Alimentation et de L'EnvironmentInventors: Noel Yves Henri Jean Genin, Jean-Christophe Audonnet, Didier Roy, Edouard Seche, Patrick Gervais, Samira Khaldi-Plassart, Romain Useo, Joelle DeConinck
-
Publication number: 20170087242Abstract: The present invention provides vectors that contain and express in vivo or in vitro one or more Hendra virus polypeptides or antigens that elicit an immune response in animal or human against Hendra virus and Nipah virus, compositions comprising said vectors and/or Hendra virus polypeptides, methods of vaccination against Hendra virus and Nipah virus, and kits for use with such methods and compositions.Type: ApplicationFiled: August 10, 2016Publication date: March 30, 2017Applicant: MERIAL, INC.Inventors: Jean-Christophe Audonnet, Jules Maarten Minke, Teshome Mebatsion, Catherine Charreyre
-
Patent number: 9555101Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising the recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.Type: GrantFiled: November 17, 2014Date of Patent: January 31, 2017Assignee: Merial, Inc.Inventors: Jean Christophe Audonnet, Jules Maarten Minke, Nikolaus Osterrieder, Guanggang Ma
-
Publication number: 20170022255Abstract: The present invention encompasses BTV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing BTV antigens. The invention also encompasses recombinant vectors encoding and expressing BTV antigens, epitopes or immunogens which can be used to protect animals, such as ovines, bovines, or caprines, against BTV.Type: ApplicationFiled: April 14, 2016Publication date: January 26, 2017Applicant: MERIAL, INC.Inventors: Jean-Christophe Audonnet, Xuan Guo, Kevin Cox
-
Publication number: 20160220659Abstract: The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.Type: ApplicationFiled: September 23, 2015Publication date: August 4, 2016Applicant: MERIAL, INC.Inventors: Jean-Christophe Audonnet, Zahia Hannas-Djebbara, Teshome Mebatsion, Yu-Wei Chiang, Justin Widener, Frédéric Reynard
-
Publication number: 20160199483Abstract: The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus.Type: ApplicationFiled: March 29, 2016Publication date: July 14, 2016Applicant: MERIAL, INC.Inventors: Jean-Christophe Audonnet, Jules Minke
-
Patent number: 9345759Abstract: The present invention encompasses BTV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing BTV antigens. The invention also encompasses recombinant vectors encoding and expressing BTV antigens, epitopes or immunogens which can be used to protect animals, such as ovines, bovines, or caprines, against BTV.Type: GrantFiled: March 11, 2011Date of Patent: May 24, 2016Assignee: MERIAL, INC.Inventors: Jean-Christophe Audonnet, Xuan Guo, Kevin Cox
-
Patent number: 9327137Abstract: The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus.Type: GrantFiled: February 25, 2011Date of Patent: May 3, 2016Assignee: MERIAL, INC.Inventors: Jean-Christophe Audonnet, Jules Minke